Valuation Method Used to Calculate Level 3 Liabilities Measured at Estimated Fair Value of Contingent Consideration Related to Acquisition (Detail) - USD ($) $ in Thousands		9 Months Ended
	Jul. 01, 2014	Dec. 31, 2016	Mar. 31, 2016
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration		$ 8,175	$ 7,563
ECP Entwicklungsgesellschaft mbH
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rate	21.50%
Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration		8,175	$ 7,563
Level 3 | ECP Entwicklungsgesellschaft mbH
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration		8,175
Level 3 | ECP Entwicklungsgesellschaft mbH | Probability weighted income approach | Clinical and regulatory milestone
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration		$ 4,607
Level 3 | ECP Entwicklungsgesellschaft mbH | Probability weighted income approach | Clinical and regulatory milestone | Contingent Consideration
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rate		8.00%
Level 3 | ECP Entwicklungsgesellschaft mbH | Probability weighted income approach | Clinical and regulatory milestone | Base Case Scenario | Contingent Consideration
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Probability of occurrence		50.00%
Level 3 | ECP Entwicklungsgesellschaft mbH | Probability weighted income approach | Clinical and regulatory milestone | Minimum | Contingent Consideration
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Projected fiscal year of payment		2019
Level 3 | ECP Entwicklungsgesellschaft mbH | Probability weighted income approach | Clinical and regulatory milestone | Minimum | Various Upside and Downside Scenarios | Contingent Consideration
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Probability of occurrence		5.00%
Level 3 | ECP Entwicklungsgesellschaft mbH | Probability weighted income approach | Clinical and regulatory milestone | Maximum | Contingent Consideration
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Projected fiscal year of payment		2022
Level 3 | ECP Entwicklungsgesellschaft mbH | Probability weighted income approach | Clinical and regulatory milestone | Maximum | Various Upside and Downside Scenarios | Contingent Consideration
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Probability of occurrence		20.00%
Level 3 | ECP Entwicklungsgesellschaft mbH | Monte Carlo simulation model | Revenue-based milestone
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration		$ 3,568
Level 3 | ECP Entwicklungsgesellschaft mbH | Monte Carlo simulation model | Revenue-based milestone | Contingent Consideration
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rate		18.00%
Expected volatility for forecasted ECP revenues		50.00%
Level 3 | ECP Entwicklungsgesellschaft mbH | Monte Carlo simulation model | Revenue-based milestone | Minimum | Contingent Consideration
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Projected fiscal year of payment		2023
Level 3 | ECP Entwicklungsgesellschaft mbH | Monte Carlo simulation model | Revenue-based milestone | Maximum | Contingent Consideration
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Projected fiscal year of payment		2035